Every Form 4 that INTEGRATED BIOPHARMA INC (INBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBP filings page.
INTEGRATED BIOPHARMA director Eric J. Friedman received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, giving him rights to purchase up to 50,000 shares once vested.
INTEGRATED BIOPHARMA INC director and 10% owner Damon DeSantis received a stock option grant covering 50,000 shares of common stock. The options carry an exercise price of $0.2000 per share and expire on June 24, 2036. Following this grant, DeSantis holds options for 50,000 shares directly. The award vests in four equal installments of 12,500 options on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning he can exercise portions of the grant over time as they vest.
INTEGRATED BIOPHARMA INC director Eric J. Friedman received a grant of stock options for 50,000 shares of Common Stock. These options have an exercise price of $0.1900 per share and expire on June 24, 2036. The grant is compensation-related rather than an open‑market purchase.
The options vest and become exercisable in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning vesting with future service periods.
INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options between September 2026 and June 2027.
Integrated BioPharma Inc. director William H. Milmoe received a grant of stock options to acquire 50,000 shares of Common Stock. The options have an exercise price of $0.19 per share and were awarded at no cost to him.
The options vest in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, and expire on June 24, 2036. This is a routine compensation-related award rather than an open-market trade.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported bona fide gifts of 11,201,964 shares of Common Stock. The transactions were coded as gifts at $0.0000 per share, indicating non-cash transfers.
The filing notes that 8,966,547 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis, and 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC. Following these transfers, associated indirect holdings total 2,374,084 shares and Milmoe directly owns 138,667 shares.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported large stock gifts involving entities he is associated with. On April 15, 2026, entities linked to him made bona fide gifts totaling 11,201,964 shares of Common Stock at a stated price of $0.00 per share.
One gift transferred 8,966,547 shares from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. Another transferred 2,235,417 shares from the Carl DeSantis Revocable Trust to the same CDDS 2.0, LLC. After these gifts, Milmoe’s reported holdings were 2,374,084 shares indirectly and 138,667 shares directly of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC major shareholder Carl DeSantis reported estate-related gift transfers of 11,201,964 shares of Common Stock. Two bona fide gifts on April 15, 2026 disposed of 8,966,547 shares held by CD Financial, LLC and 2,235,417 shares held by the Carl DeSantis Revocable Trust.
According to the footnotes, both blocks were transferred to CDDS 2.0, LLC, a Florida limited liability company controlled by Damon DeSantis. The reporting person is noted as deceased, and these are indirect holdings. After the second transfer, the filing shows 0 shares of Common Stock indirectly owned.
Integrated BioPharma director and 10% owner Damon DeSantis reported two bona fide gift transfers of Common Stock involving related entities. The filing shows gifts of 8,966,547 and 2,235,417 shares, for a total of 11,201,964 shares, at a stated price of $0 per share.
According to the footnotes, these shares were transferred from CD Financial, LLC and the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by DeSantis. After these transfers, DeSantis indirectly holds 12,733,058 shares of Integrated BioPharma Common Stock through CDDS 2.0, LLC.
INTEGRATED BIOPHARMA INC insider reporting reflects non-market gifts of Common Stock by entities associated with the late Carl DeSantis. CD Financial, LLC transferred 1,356,293 shares and the Carl DeSantis Revocable Trust transferred 7,392 shares to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. After these bona fide gifts, a total of 11,366,673 shares of Common Stock remain indirectly held through CD Financial, LLC, the revocable trust and the Estate of Carl DeSantis.
Integrated BioPharma director and 10% owner William H. Milmoe reported two bona fide gifts of Common Stock made through entities he is associated with. On March 24, 2026, 1,356,293 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, and 7,392 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC controlled by Damon DeSantis. These are non-cash, indirect transfers rather than market sales. After the gifts, Milmoe’s reported holdings across CD Financial, the revocable trust, the Estate of Carl DeSantis, and his direct ownership total 11,505,340 shares of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC director Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of Common Stock. The transactions, coded as gifts, were recorded at a price of $0.00 per share and are held indirectly through CDDS 2.0, LLC.
Footnotes state that 1,356,293 shares were transferred from CD Financial, LLC and 7,392 shares from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, which is controlled by DeSantis. Following these transfers, he indirectly holds 1,363,685 shares of the company’s common stock.
Integrated BioPharma Inc. reported an equity award to a senior insider. On 12/09/2025, Co-Chief Executive Officer, director and 10% owner Christina Kay received a stock option covering 140,000 shares of common stock at an exercise price of $0.35 per share. Following this grant, she beneficially owns 140,000 derivative securities in the form of this option. The option vests in three equal annual installments, with the first tranche vesting on December 9, 2026, aligning her compensation with longer-term shareholder performance.
Integrated BioPharma Inc. reported a new equity award to its Co-Chief Executive Officer and director, Riva Sheppard. On 12/09/2025, Sheppard received a stock option to purchase 140,000 shares of common stock at an exercise price of $0.35 per share. The option has an expiration date of December 9, 2035 and vests in three equal annual installments, with the first tranche vesting on December 9, 2026. Following this grant, Sheppard holds 140,000 derivative securities directly.
Integrated BioPharma Inc. reported a new stock option grant to its Chief Financial Officer, Dina L. Masi. On 12/09/2025, she received an option to purchase 140,000 shares of the company’s common stock at an exercise price of $0.31 per share. The option has an expiration date of 12/09/2035, giving a long-term window to exercise.
The option vests in three equal annual installments, with the first installment becoming exercisable on December 9, 2026. This means the grant is designed as a multi-year incentive, aligning the CFO’s potential equity gains with the company’s performance over time.